Ocular Therapeutix
OCUL
72 hedge funds and large institutions have $128M invested in Ocular Therapeutix in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 13 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 12
33% more capital invested
Capital invested by funds: $96.4M → $128M (+$32.1M)
17% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.11M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 75 → 72 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.89M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.65M |
| 3 |
CCI
Columbus Circle Investors
|
+$1.29M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$861K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$610K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$6.92M |
| 2 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
-$1.75M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.29M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.2M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$422K |
OCUL Hedge Fund Activity: Q3 2016 in Review
72 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2016, worth a combined $128M — up 33% from $96.4M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of OCUL and 10 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 30 added.
The largest buyer was Morgan Stanley, adding an estimated $2.89M. The largest seller was Federated Hermes, cutting an estimated $6.92M.
- 72 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2016, down from 75 in Q2 2016.
- Funds reported $128M of Ocular Therapeutix stock for Q3 2016, up 33% quarter-over-quarter.
- 10 funds opened new Ocular Therapeutix positions in Q3 2016 and 13 closed out, a net change of -3 holders.
- The largest Ocular Therapeutix buyer in Q3 2016 was Morgan Stanley, an estimated $2.89M added.
- The largest Ocular Therapeutix seller in Q3 2016 was Federated Hermes, an estimated $6.92M sold.
Based on aggregated 13F filings for Q3 2016.